25 XP   0   0   10

Apteki 36
Buy, Hold or Sell?

Let's analyse Apteki 36 together

PenkeI guess you are interested in Apteki 36. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Apteki 36. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Apteki 36

I send you an email if I find something interesting about Apteki 36.

Quick analysis of Apteki 36 (30 sec.)










What can you expect buying and holding a share of Apteki 36? (30 sec.)

How much money do you get?

How much money do you get?
₽0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₽-0.84
Expected worth in 1 year
₽-0.73
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
₽0.12
Return On Investment
0.9%

For what price can you sell your share?

Current Price per Share
₽12.81
Expected price per share
₽12.20 - ₽14.40
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Apteki 36 (5 min.)




Live pricePrice per Share (EOD)

₽12.81

Intrinsic Value Per Share

₽-0.78 - ₽21.10

Total Value Per Share

₽-1.62 - ₽20.25

2. Growth of Apteki 36 (5 min.)




Is Apteki 36 growing?

Current yearPrevious yearGrowGrow %
How rich?-$70m-$72.5m$2.4m3.5%

How much money is Apteki 36 making?

Current yearPrevious yearGrowGrow %
Making money$2.4m-$10.3m$12.7m526.0%
Net Profit Margin0.4%-2.2%--

How much money comes from the company's main activities?

3. Financial Health of Apteki 36 (5 min.)




4. Comparing to competitors in the Pharmaceutical Retailers industry (5 min.)




  Industry Rankings (Pharmaceutical Retailers)  


Richest
#45 / 47

Most Revenue
#14 / 47

Most Profit
#22 / 47
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Apteki 36? (5 min.)

Welcome investor! Apteki 36's management wants to use your money to grow the business. In return you get a share of Apteki 36.

What can you expect buying and holding a share of Apteki 36?

First you should know what it really means to hold a share of Apteki 36. And how you can make/lose money.

Speculation

The Price per Share of Apteki 36 is ₽12.81. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Apteki 36.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Apteki 36, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₽-0.84. Based on the TTM, the Book Value Change Per Share is ₽0.03 per quarter. Based on the YOY, the Book Value Change Per Share is ₽-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₽0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Apteki 36.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.000.0%0.000.0%0.000.0%-0.01-0.1%-0.01-0.1%
Usd Book Value Change Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Price Per Share0.13-0.13-0.15-0.12-0.14-
Price to Earnings Ratio395.89-395.89--111.65-57.77--126.83-
Price-to-Total Gains Ratio395.89-395.89--111.65-59.12-35.42-
Price to Book Ratio-13.73--13.73--15.94--10.70-26.97-
Price-to-Total Gains Ratio395.89-395.89--111.65-59.12-35.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.139629
Number of shares7161
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (7161 shares)2.2815.11
Gains per Year (7161 shares)9.1260.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109-106050
201880121110
3027170181170
4036260242230
5046350302290
6055440363350
7064530423410
8073620484470
9082710544530
10091800605590

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%2.08.00.020.0%2.014.00.012.5%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%7.09.00.043.8%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.016.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%7.09.00.043.8%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Apteki 36

About Apteki 36

Public Joint-Stock Company Pharmacy Chain 36.6 operates pharmacies in Russia. Its pharmacies offer health and beauty products. The company serves customers under the 36.6, Romir, and Gorzdrav brands. Public Joint-Stock Company Pharmacy Chain 36.6 was founded in 1991 and is based in Moscow, Russia.

Fundamental data was last updated by Penke on 2023-11-18 15:25:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Apteki 36.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Apteki 36 earns for each руб1 of revenue.

  • Above 10% is considered healthy but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • A Net Profit Margin of 0.4% means that руб0.00 for each руб1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Apteki 36:

  • The MRQ is 0.4%. The company is not making a profit/loss.
  • The TTM is 0.4%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.4%TTM0.4%0.0%
TTM0.4%YOY-2.2%+2.5%
TTM0.4%5Y-15.0%+15.4%
5Y-15.0%10Y-21.1%+6.1%
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4%0.6%-0.2%
TTM0.4%-+0.4%
YOY-2.2%1.3%-3.5%
5Y-15.0%1.3%-16.3%
10Y-21.1%1.4%-22.5%
1.1.2. Return on Assets

Shows how efficient Apteki 36 is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • 0.5% Return on Assets means that Apteki 36 generated руб0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Apteki 36:

  • The MRQ is 0.5%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.5%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.5%TTM0.5%0.0%
TTM0.5%YOY-2.5%+3.0%
TTM0.5%5Y-20.2%+20.7%
5Y-20.2%10Y-43.0%+22.7%
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5%0.3%+0.2%
TTM0.5%0.2%+0.3%
YOY-2.5%0.4%-2.9%
5Y-20.2%0.4%-20.6%
10Y-43.0%0.3%-43.3%
1.1.3. Return on Equity

Shows how efficient Apteki 36 is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • 0.0% Return on Equity means Apteki 36 generated руб0.00 for each руб1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Apteki 36:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-1.3%+1.3%
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.9%-1.9%
TTM-1.7%-1.7%
YOY-2.4%-2.4%
5Y-2.0%-2.0%
10Y-1.3%2.1%-3.4%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Apteki 36.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Apteki 36 is operating .

  • Measures how much profit Apteki 36 makes for each руб1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • An Operating Margin of 7.5% means the company generated руб0.08  for each руб1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Apteki 36:

  • The MRQ is 7.5%. The company is operating less efficient.
  • The TTM is 7.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ7.5%TTM7.5%0.0%
TTM7.5%YOY2.7%+4.8%
TTM7.5%5Y-5.2%+12.8%
5Y-5.2%10Y-12.5%+7.3%
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5%-6.0%+13.5%
TTM7.5%-4.0%+11.5%
YOY2.7%2.2%+0.5%
5Y-5.2%0.9%-6.1%
10Y-12.5%0.9%-13.4%
1.2.2. Operating Ratio

Measures how efficient Apteki 36 is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceutical Retailers industry mean).
  • An Operation Ratio of 0.92 means that the operating costs are руб0.92 for each руб1 in net sales.

Let's take a look of the Operating Ratio trends of Apteki 36:

  • The MRQ is 0.919. The company is less efficient in keeping operating costs low.
  • The TTM is 0.919. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.919TTM0.9190.000
TTM0.919YOY0.971-0.053
TTM0.9195Y0.991-0.072
5Y0.99110Y1.027-0.036
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9191.665-0.746
TTM0.9191.595-0.676
YOY0.9711.574-0.603
5Y0.9911.515-0.524
10Y1.0271.296-0.269
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Apteki 36.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Apteki 36 is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceutical Retailers industry mean).
  • A Current Ratio of 0.54 means the company has руб0.54 in assets for each руб1 in short-term debts.

Let's take a look of the Current Ratio trends of Apteki 36:

  • The MRQ is 0.537. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.537. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.537TTM0.5370.000
TTM0.537YOY0.467+0.070
TTM0.5375Y0.616-0.079
5Y0.61610Y0.598+0.018
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5371.181-0.644
TTM0.5371.180-0.643
YOY0.4671.279-0.812
5Y0.6161.436-0.820
10Y0.5981.137-0.539
1.3.2. Quick Ratio

Measures if Apteki 36 is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • A Quick Ratio of 0.23 means the company can pay off руб0.23 for each руб1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Apteki 36:

  • The MRQ is 0.228. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.228. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.228TTM0.2280.000
TTM0.228YOY0.230-0.001
TTM0.2285Y0.295-0.066
5Y0.29510Y0.256+0.038
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2280.527-0.299
TTM0.2280.507-0.279
YOY0.2300.521-0.291
5Y0.2950.559-0.264
10Y0.2560.658-0.402
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Apteki 36.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Apteki 36 assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Apteki 36 to Pharmaceutical Retailers industry mean.
  • A Debt to Asset Ratio of 1.15 means that Apteki 36 assets are financed with 114.7% credit (debt) and the remaining percentage (100% - 114.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Apteki 36:

  • The MRQ is 1.147. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.147. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.147TTM1.1470.000
TTM1.147YOY1.176-0.028
TTM1.1475Y1.455-0.308
5Y1.45510Y1.538-0.083
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1470.660+0.487
TTM1.1470.658+0.489
YOY1.1760.667+0.509
5Y1.4550.630+0.825
10Y1.5380.592+0.946
1.4.2. Debt to Equity Ratio

Measures if Apteki 36 is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • A Debt to Equity ratio of 0.0% means that company has руб0.00 debt for each руб1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Apteki 36:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y1.869-1.869
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.585-1.585
TTM-1.693-1.693
YOY-1.814-1.814
5Y-1.974-1.974
10Y1.8691.569+0.300
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Apteki 36

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every руб1 in earnings Apteki 36 generates.

  • Above 15 is considered overpriced but always compare Apteki 36 to the Pharmaceutical Retailers industry mean.
  • A PE ratio of 395.89 means the investor is paying руб395.89 for every руб1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Apteki 36:

  • The EOD is 438.322. Based on the earnings, the company is expensive. -2
  • The MRQ is 395.893. Based on the earnings, the company is expensive. -2
  • The TTM is 395.893. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD438.322MRQ395.893+42.429
MRQ395.893TTM395.8930.000
TTM395.893YOY-111.645+507.538
TTM395.8935Y57.766+338.127
5Y57.76610Y-126.828+184.594
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
EOD438.3224.979+433.343
MRQ395.8934.433+391.460
TTM395.89310.474+385.419
YOY-111.6456.676-118.321
5Y57.7668.295+49.471
10Y-126.82813.396-140.224
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Apteki 36:

  • The EOD is 17.580. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 15.878. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 15.878. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD17.580MRQ15.878+1.702
MRQ15.878TTM15.8780.000
TTM15.878YOY47.223-31.345
TTM15.8785Y2.853+13.025
5Y2.85310Y-29.888+32.741
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
EOD17.5802.169+15.411
MRQ15.8782.122+13.756
TTM15.878-0.018+15.896
YOY47.2231.041+46.182
5Y2.853-1.638+4.491
10Y-29.888-0.477-29.411
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Apteki 36 is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceutical Retailers industry mean).
  • A PB ratio of -13.73 means the investor is paying руб-13.73 for each руб1 in book value.

Let's take a look of the Price to Book Ratio trends of Apteki 36:

  • The EOD is -15.199. Based on the equity, the company is expensive. -2
  • The MRQ is -13.728. Based on the equity, the company is expensive. -2
  • The TTM is -13.728. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.199MRQ-13.728-1.471
MRQ-13.728TTM-13.7280.000
TTM-13.728YOY-15.940+2.212
TTM-13.7285Y-10.702-3.026
5Y-10.70210Y26.974-37.676
Compared to industry (Pharmaceutical Retailers)
PeriodCompanyIndustry (mean)+/- 
EOD-15.1991.032-16.231
MRQ-13.7281.068-14.796
TTM-13.7281.297-15.025
YOY-15.9401.961-17.901
5Y-10.7021.905-12.607
10Y26.9742.621+24.353
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Apteki 36 compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0290.0290%-0.125+526%0.194-85%-0.132+553%
Book Value Per Share---0.843-0.8430%-0.872+3%-2.075+146%-1.343+59%
Current Ratio--0.5370.5370%0.467+15%0.616-13%0.598-10%
Debt To Asset Ratio--1.1471.1470%1.176-2%1.455-21%1.538-25%
Debt To Equity Ratio----0%-0%-0%1.869-100%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0290.0290%-0.125+526%-0.687+2450%-0.778+2761%
Free Cash Flow Per Share--0.7290.7290%0.294+148%-0.296+141%-0.425+158%
Free Cash Flow To Equity Per Share---0.125-0.1250%-2.430+1839%-0.003-98%0.009-1538%
Gross Profit Margin---0.650-0.6500%1.224-153%0.878-174%1.583-141%
Intrinsic Value_10Y_max--21.098--------
Intrinsic Value_10Y_min---0.779--------
Intrinsic Value_1Y_max--0.543--------
Intrinsic Value_1Y_min---0.341--------
Intrinsic Value_3Y_max--2.830--------
Intrinsic Value_3Y_min---0.803--------
Intrinsic Value_5Y_max--6.559--------
Intrinsic Value_5Y_min---1.018--------
Market Cap97745810964.480+10%88284119366.82088284119366.8200%106063030181.400-17%86910618499.212+2%94701278526.534-7%
Net Profit Margin--0.0040.0040%-0.022+670%-0.150+4071%-0.211+5685%
Operating Margin--0.0750.0750%0.027+178%-0.052+169%-0.125+266%
Operating Ratio--0.9190.9190%0.971-5%0.991-7%1.027-11%
Pb Ratio-15.199-11%-13.728-13.7280%-15.940+16%-10.702-22%26.974-151%
Pe Ratio438.322+10%395.893395.8930%-111.645+128%57.766+585%-126.828+132%
Price Per Share12.810+10%11.57011.5700%13.900-17%11.390+2%12.411-7%
Price To Free Cash Flow Ratio17.580+10%15.87815.8780%47.223-66%2.853+456%-29.888+288%
Price To Total Gains Ratio438.322+10%395.893395.8930%-111.646+128%59.125+570%35.421+1018%
Quick Ratio--0.2280.2280%0.230-1%0.295-22%0.256-11%
Return On Assets--0.0050.0050%-0.025+591%-0.202+4059%-0.430+8505%
Return On Equity----0%-0%-0%-0.0130%
Total Gains Per Share--0.0290.0290%-0.125+526%0.194-85%-0.132+553%
Usd Book Value---70097900.000-70097900.0000%-72528600.000+3%-172553540.000+146%-111736990.000+59%
Usd Book Value Change Per Share--0.0000.0000%-0.001+526%0.002-85%-0.001+553%
Usd Book Value Per Share---0.009-0.0090%-0.010+3%-0.023+146%-0.015+59%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0000.0000%-0.001+526%-0.007+2450%-0.008+2761%
Usd Free Cash Flow--60604000.00060604000.0000%24481400.000+148%-24644900.000+141%-35348700.000+158%
Usd Free Cash Flow Per Share--0.0080.0080%0.003+148%-0.003+141%-0.005+158%
Usd Free Cash Flow To Equity Per Share---0.001-0.0010%-0.026+1839%0.000-98%0.000-1538%
Usd Market Cap1065429339.513+10%962296901.098962296901.0980%1156087028.977-17%947325741.641+2%1032243935.939-7%
Usd Price Per Share0.140+10%0.1260.1260%0.152-17%0.124+2%0.135-7%
Usd Profit--2430700.0002430700.0000%-10355000.000+526%-73141180.000+3109%-72687740.000+3090%
Usd Revenue--643623200.000643623200.0000%480733600.000+34%508227760.000+27%425322360.000+51%
Usd Total Gains Per Share--0.0000.0000%-0.001+526%0.002-85%-0.001+553%
 EOD+5 -3MRQTTM+0 -0YOY+25 -75Y+20 -1210Y+23 -10

3.2. Fundamental Score

Let's check the fundamental score of Apteki 36 based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15438.322
Price to Book Ratio (EOD)Between0-1-15.199
Net Profit Margin (MRQ)Greater than00.004
Operating Margin (MRQ)Greater than00.075
Quick Ratio (MRQ)Greater than10.228
Current Ratio (MRQ)Greater than10.537
Debt to Asset Ratio (MRQ)Less than11.147
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.005
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Apteki 36 based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5020.556
Ma 20Greater thanMa 5014.529
Ma 50Greater thanMa 10015.568
Ma 100Greater thanMa 20016.120
OpenGreater thanClose12.800
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Income before Tax  -22,757,00014,012,000-8,745,0008,102,000-643,000-799,000-1,442,0001,853,000411,000
Net Income  -22,977,00014,122,000-8,855,0007,863,000-992,00042,000-950,0001,173,000223,000
Net Income from Continuing Operations  -22,977,00014,122,000-8,855,0007,863,000-992,00042,000-950,0001,173,000223,000



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in RUB. All numbers in thousands.

Summary
Total Assets43,618,000
Total Liabilities50,049,000
Total Stockholder Equity-6,431,000
 As reported
Total Liabilities 50,049,000
Total Stockholder Equity+ -6,431,000
Total Assets = 43,618,000

Assets

Total Assets43,618,000
Total Current Assets14,797,000
Long-term Assets14,797,000
Total Current Assets
Cash And Cash Equivalents 811,000
Net Receivables 5,478,000
Inventory 8,477,000
Other Current Assets 31,000
Total Current Assets  (as reported)14,797,000
Total Current Assets  (calculated)14,797,000
+/-0
Long-term Assets
Property Plant Equipment 14,644,000
Goodwill 4,171,000
Intangible Assets 9,326,000
Long-term Assets  (as reported)28,821,000
Long-term Assets  (calculated)28,141,000
+/- 680,000

Liabilities & Shareholders' Equity

Total Current Liabilities27,534,000
Long-term Liabilities22,515,000
Total Stockholder Equity-6,431,000
Total Current Liabilities
Short-term Debt 10,281,000
Short Long Term Debt 5,936,000
Accounts payable 14,639,000
Other Current Liabilities 228,000
Total Current Liabilities  (as reported)27,534,000
Total Current Liabilities  (calculated)31,084,000
+/- 3,550,000
Long-term Liabilities
Long term Debt 12,978,000
Capital Lease Obligations 13,535,000
Long-term Liabilities  (as reported)22,515,000
Long-term Liabilities  (calculated)26,513,000
+/- 3,998,000
Total Stockholder Equity
Common Stock4,883,000
Retained Earnings -55,895,000
Other Stockholders Equity 44,581,000
Total Stockholder Equity (as reported)-6,431,000
Total Stockholder Equity (calculated)-6,431,000
+/-0
Other
Capital Stock4,883,000
Cash and Short Term Investments 811,000
Common Stock Shares Outstanding 7,630,434
Current Deferred Revenue2,386,000
Liabilities and Stockholders Equity 43,618,000
Net Debt 31,638,000
Net Invested Capital 12,483,000
Net Working Capital -12,737,000
Short Long Term Debt Total 32,449,000



Balance Sheet

Currency in RUB. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
> Total Assets 
19,909,689
17,302,996
17,267,700
18,779,100
21,867,000
22,241,000
3,798,000
32,550,000
27,314,000
44,763,000
39,909,000
32,719,000
32,620,000
54,428,000
37,831,000
43,618,000
43,618,00037,831,00054,428,00032,620,00032,719,00039,909,00044,763,00027,314,00032,550,0003,798,00022,241,00021,867,00018,779,10017,267,70017,302,99619,909,689
   > Total Current Assets 
8,897,357
8,682,022
8,890,300
10,508,400
13,016,000
12,909,000
2,662,000
18,453,000
9,258,000
13,133,000
15,753,000
11,053,000
14,230,000
30,336,000
13,500,000
14,797,000
14,797,00013,500,00030,336,00014,230,00011,053,00015,753,00013,133,0009,258,00018,453,0002,662,00012,909,00013,016,00010,508,4008,890,3008,682,0228,897,357
       Cash And Cash Equivalents 
807,955
706,193
737,600
1,021,200
889,000
838,000
489,000
392,000
284,000
585,000
659,000
503,000
847,000
1,003,000
1,727,000
811,000
811,0001,727,0001,003,000847,000503,000659,000585,000284,000392,000489,000838,000889,0001,021,200737,600706,193807,955
       Short-term Investments 
0
0
0
0
280,000
0
0
0
0
0
0
0
0
0
0
0
00000000000280,0000000
       Net Receivables 
0
0
0
0
7,027,000
6,555,000
-99,000
7,565,000
3,632,000
3,703,000
5,850,000
2,993,000
5,011,000
16,104,000
4,907,000
5,478,000
5,478,0004,907,00016,104,0005,011,0002,993,0005,850,0003,703,0003,632,0007,565,000-99,0006,555,0007,027,0000000
       Inventory 
4,242,728
3,326,310
3,454,900
4,008,900
3,292,000
3,398,000
1,705,000
9,486,000
4,272,000
7,103,000
7,747,000
6,899,000
7,548,000
5,232,000
6,404,000
8,477,000
8,477,0006,404,0005,232,0007,548,0006,899,0007,747,0007,103,0004,272,0009,486,0001,705,0003,398,0003,292,0004,008,9003,454,9003,326,3104,242,728
       Other Current Assets 
3,846,674
4,649,518
4,697,800
5,478,300
8,555,000
8,673,000
468,000
8,575,000
4,702,000
5,445,000
7,347,000
3,651,000
5,835,000
24,101,000
462,000
31,000
31,000462,00024,101,0005,835,0003,651,0007,347,0005,445,0004,702,0008,575,000468,0008,673,0008,555,0005,478,3004,697,8004,649,5183,846,674
   > Long-term Assets 
11,012,333
8,620,974
8,377,400
8,270,700
8,851,000
9,332,000
1,136,000
14,097,000
18,056,000
31,630,000
24,156,000
21,666,000
18,390,000
24,092,000
24,331,000
28,821,000
28,821,00024,331,00024,092,00018,390,00021,666,00024,156,00031,630,00018,056,00014,097,0001,136,0009,332,0008,851,0008,270,7008,377,4008,620,97411,012,333
       Property Plant Equipment 
4,607,508
3,336,239
3,009,100
2,858,600
3,295,000
3,775,000
1,019,000
1,584,000
1,004,000
1,026,000
773,000
9,928,000
8,505,000
11,211,000
10,911,000
14,644,000
14,644,00010,911,00011,211,0008,505,0009,928,000773,0001,026,0001,004,0001,584,0001,019,0003,775,0003,295,0002,858,6003,009,1003,336,2394,607,508
       Goodwill 
0
0
0
0
4,876,000
4,876,000
0
9,527,000
9,527,000
9,527,000
8,123,000
3,381,000
3,381,000
3,381,000
3,582,000
4,171,000
4,171,0003,582,0003,381,0003,381,0003,381,0008,123,0009,527,0009,527,0009,527,00004,876,0004,876,0000000
       Intangible Assets 
0
0
0
0
0
422,000
17,000
2,170,000
6,752,000
20,400,000
14,821,000
7,961,000
6,256,000
9,116,000
9,278,000
9,326,000
9,326,0009,278,0009,116,0006,256,0007,961,00014,821,00020,400,0006,752,0002,170,00017,000422,00000000
       Long-term Assets Other 
43,042
37,557
207,200
217,400
238,000
229,000
0
694,000
416,000
135,000
8,000
28,000
18,390,000
384,000
0
0
00384,00018,390,00028,0008,000135,000416,000694,0000229,000238,000217,400207,20037,55743,042
> Total Liabilities 
14,344,733
12,371,343
12,783,300
13,962,500
17,669,000
18,567,000
14,436,000
32,308,000
25,927,000
45,294,000
53,727,000
69,527,000
56,176,000
60,132,000
44,485,000
50,049,000
50,049,00044,485,00060,132,00056,176,00069,527,00053,727,00045,294,00025,927,00032,308,00014,436,00018,567,00017,669,00013,962,50012,783,30012,371,34314,344,733
   > Total Current Liabilities 
13,707,301
11,429,732
7,932,400
7,980,600
15,848,000
15,837,000
7,951,000
24,042,000
13,191,000
27,896,000
25,123,000
36,794,000
26,224,000
24,573,000
28,894,000
27,534,000
27,534,00028,894,00024,573,00026,224,00036,794,00025,123,00027,896,00013,191,00024,042,0007,951,00015,837,00015,848,0007,980,6007,932,40011,429,73213,707,301
       Short-term Debt 
6,710,348
3,656,433
2,825,300
6,867,400
7,996,000
8,387,000
2,124,000
4,710,000
892,000
3,163,000
3,817,000
22,903,000
10,851,000
14,377,000
15,892,000
10,281,000
10,281,00015,892,00014,377,00010,851,00022,903,0003,817,0003,163,000892,0004,710,0002,124,0008,387,0007,996,0006,867,4002,825,3003,656,4336,710,348
       Short Long Term Debt 
0
0
0
0
9,994,000
10,910,000
8,549,000
10,883,000
324,000
3,163,000
3,817,000
18,451,000
6,499,000
10,151,000
11,634,000
5,936,000
5,936,00011,634,00010,151,0006,499,00018,451,0003,817,0003,163,000324,00010,883,0008,549,00010,910,0009,994,0000000
       Accounts payable 
4,949,931
6,102,919
3,838,600
3,313,200
5,793,000
5,888,000
3,926,000
17,370,000
11,018,000
21,534,000
18,260,000
11,271,000
13,061,000
8,073,000
10,647,000
14,639,000
14,639,00010,647,0008,073,00013,061,00011,271,00018,260,00021,534,00011,018,00017,370,0003,926,0005,888,0005,793,0003,313,2003,838,6006,102,9194,949,931
       Other Current Liabilities 
2,047,022
1,670,380
1,268,500
-2,200,000
2,059,000
1,562,000
1,901,000
1,962,000
1,281,000
3,199,000
1,991,000
1,926,000
2,312,000
2,123,000
93,000
228,000
228,00093,0002,123,0002,312,0001,926,0001,991,0003,199,0001,281,0001,962,0001,901,0001,562,0002,059,000-2,200,0001,268,5001,670,3802,047,022
   > Long-term Liabilities 
637,431
941,611
4,850,900
5,981,900
1,821,000
2,730,000
6,485,000
8,266,000
12,736,000
17,398,000
28,604,000
32,733,000
29,952,000
35,559,000
15,591,000
22,515,000
22,515,00015,591,00035,559,00029,952,00032,733,00028,604,00017,398,00012,736,0008,266,0006,485,0002,730,0001,821,0005,981,9004,850,900941,611637,431
       Long term Debt Total 
0
0
0
0
0
0
0
0
12,315,000
17,129,000
28,356,000
32,325,000
29,749,000
35,338,000
15,426,000
0
015,426,00035,338,00029,749,00032,325,00028,356,00017,129,00012,315,00000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
420,000
269,000
248,000
408,000
203,000
221,000
0
0
00221,000203,000408,000248,000269,000420,00000000000
       Deferred Long Term Liability 
0
0
0
0
181,000
291,000
1,000
1,000
1,000
1,000
0
0
0
0
0
0
0000001,0001,0001,0001,000291,000181,0000000
> Total Stockholder Equity
1,862,323
262,484
2,176,400
2,159,000
1,195,000
214,000
-10,683,000
-740,000
1,387,000
-531,000
-13,818,000
-36,808,000
-23,556,000
-5,704,000
-6,654,000
-6,431,000
-6,431,000-6,654,000-5,704,000-23,556,000-36,808,000-13,818,000-531,0001,387,000-740,000-10,683,000214,0001,195,0002,159,0002,176,400262,4841,862,323
   Common Stock
4,864
5,851
6,100
6,700
67,000
67,000
67,000
67,000
625,000
1,492,000
1,492,000
1,492,000
4,293,000
4,883,000
4,883,000
4,883,000
4,883,0004,883,0004,883,0004,293,0001,492,0001,492,0001,492,000625,00067,00067,00067,00067,0006,7006,1005,8514,864
   Retained Earnings -55,895,000-56,118,000-55,168,000-61,519,000-52,664,000-29,687,000-16,590,000-7,245,000-6,985,000-17,010,000-6,485,000-5,504,000-4,168,100-3,169,300-3,317,416-1,372,691
   Capital Surplus 
0
0
0
0
0
0
0
0
8,007,000
14,567,000
14,377,000
14,364,000
33,670,000
44,581,000
44,581,000
0
044,581,00044,581,00033,670,00014,364,00014,377,00014,567,0008,007,00000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
3,230,149
3,574,050
5,339,600
6,320,400
6,632,000
10,001,000
8,321,000
6,272,000
8,191,000
14,982,000
14,963,000
15,040,000
33,670,000
44,581,000
44,581,000
44,581,000
44,581,00044,581,00044,581,00033,670,00015,040,00014,963,00014,982,0008,191,0006,272,0008,321,00010,001,0006,632,0006,320,4005,339,6003,574,0503,230,149



Balance Sheet

Currency in RUB. All numbers in thousands.




Cash Flow

Currency in RUB. All numbers in thousands.




Income Statement

Currency in RUB. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue59,048,000
Cost of Revenue-38,855,000
Gross Profit20,193,00020,193,000
 
Operating Income (+$)
Gross Profit20,193,000
Operating Expense-15,398,000
Operating Income4,456,0004,795,000
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,062,000
Selling And Marketing Expenses368,000
Operating Expense15,398,0001,430,000
 
Net Interest Income (+$)
Interest Income4,065,000
Interest Expense-4,241,000
Other Finance Cost-4,610,000
Net Interest Income-4,786,000
 
Pretax Income (+$)
Operating Income4,456,000
Net Interest Income-4,786,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)411,0008,501,000
EBIT - interestExpense = 215,000
411,000
4,464,000
Interest Expense4,241,000
Earnings Before Interest and Taxes (EBIT)4,456,0004,652,000
Earnings Before Interest and Taxes (EBITDA)10,245,000
 
After tax Income (+$)
Income Before Tax411,000
Tax Provision-188,000
Net Income From Continuing Ops223,000223,000
Net Income223,000
Net Income Applicable To Common Shares223,000
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses54,253,000
Total Other Income/Expenses Net-4,045,0004,786,000
 

Technical Analysis of Apteki 36
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Apteki 36. The general trend of Apteki 36 is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Apteki 36's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Apteki 36.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 12.89 < 14.11 < 14.40.

The bearish price targets are: 12.30 > 12.27 > 12.20.

Tweet this
Apteki 36 Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Apteki 36. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Apteki 36 Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Apteki 36. The current macd is -0.71635308.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Apteki 36 price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Apteki 36. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Apteki 36 price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Apteki 36 Daily Moving Average Convergence/Divergence (MACD) ChartApteki 36 Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Apteki 36. The current adx is 35.35.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Apteki 36 shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Apteki 36 Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Apteki 36. The current sar is 13.77.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Apteki 36 Daily Parabolic SAR Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Apteki 36. The current rsi is 20.56. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Apteki 36 Daily Relative Strength Index (RSI) ChartApteki 36 Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Apteki 36. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Apteki 36 price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Apteki 36 Daily Stochastic Oscillator ChartApteki 36 Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Apteki 36. The current cci is -163.2735856.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Apteki 36 Daily Commodity Channel Index (CCI) ChartApteki 36 Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Apteki 36. The current cmo is -70.50797983.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Apteki 36 Daily Chande Momentum Oscillator (CMO) ChartApteki 36 Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Apteki 36. The current willr is -76.1624485.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Apteki 36 is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Apteki 36 Daily Williams %R ChartApteki 36 Daily Williams %R Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Apteki 36.

Apteki 36 Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Apteki 36. The current atr is 0.57817393.

Apteki 36 Daily Average True Range (ATR) ChartApteki 36 Daily Average True Range (ATR) Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Apteki 36. The current obv is 143,965,690.

Apteki 36 Daily On-Balance Volume (OBV) ChartApteki 36 Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Apteki 36. The current mfi is 16.27.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Apteki 36 Daily Money Flow Index (MFI) ChartApteki 36 Daily Money Flow Index (MFI) Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Apteki 36.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-07-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-07-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-07-31MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-08-03STOCH SHORT EXITThe %K line crosses above the %D line.
2023-08-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-08-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-08-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-08-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-08-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-08-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-09-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-09-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-09-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-10-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-10-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-10-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-31STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Apteki 36 Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Apteki 36 based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5020.556
Ma 20Greater thanMa 5014.529
Ma 50Greater thanMa 10015.568
Ma 100Greater thanMa 20016.120
OpenGreater thanClose12.800
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Apteki 36 with someone you think should read this too:
  • Are you bullish or bearish on Apteki 36? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Apteki 36? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Apteki 36

I send you an email if I find something interesting about Apteki 36.


Comments

How you think about this?

Leave a comment
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Stay informed about Apteki 36.

Receive notifications about Apteki 36 in your mailbox!